123I-MIBG, 18F-DOPA and 18F-FDG in a patient with MEN2 syndrome and recurrent pheochromocytoma;123I-MIBG, 18F-DOPA y 18F-FDG en una paciente con síndrome de neoplasia endocrina múltiple tipo 2 y recidiva de feocromocitoma

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 32, Issue 4, 2013, Pages 263-265

  Cuenca Cuenca, J I ^a   Marin Oyaga V A ^a   Borrego Dorado, I ^a   Navarro Gonzalez E ^a   Martos Martinez J M ^a   Vazquez Albertino R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

123I Metaiodobenzyl Guanidine; 123I metayodobencilguanidina; 2 18F 2 deoxy D glucosa; 2 18F 2 fluoro deoxy D glucose; 6 18F Fluoro L Dihydroxyphenylalanine; 6 L 18F fluorodihidroxifenilalanina; Feocromocitoma; Pheochromocytoma; Positron emission tomography computed tomography; Tomograf a por emisi n de positrones tomograf a computadorizada

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; FLUORODEOXYGLUCOSE F 18; METADRENALIN; (3 IODOBENZYL)GUANIDINE; DOPA; RADIOPHARMACEUTICAL AGENT; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

ADRENALECTOMY; ARTICLE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ENDOCRINE TUMOR; FEMALE; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA SYNDROME TYPE 2; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; SCINTIGRAPHY; TUMOR DIAGNOSIS; TUMOR RECURRENCE; URINE LEVEL; ADRENAL TUMOR; ADULT; ANALOGS AND DERIVATIVES; COMPLICATION; DIAGNOSTIC USE; MULTIPLE CANCER; SCINTISCANNING; SIPPLE SYNDROME;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; ADULT; DIHYDROXYPHENYLALANINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS;

EID: 84879258016     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2012.11.006     Document Type: Article

References (9)

1. Guller U., Turek J., Eubanks S., Delong E.R., Oertli D., Feldman J.M. Detecting pheochromocytoma: defining the most sensitive test. Ann Surg 2006, 243:102-107.
2. Ilias I., Pacak K. Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome. Endocr Regul 2009, 43:89-93.
3. Havekes B., Lai E.W., Corssmit E.P., Romijn J.A., Timmers H.J., Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging 2008, 52:419-429.
4. Hoegerle S., Nitzsche E., Altehoefer C., Ghanem N., Manz T., Brink I., et al. Pheochromocytomas: detection with 18F DOPA whole body PET - Initial results. Radiology 2002, 222:507-512.
5. Pacak K., Eisenhofer G., Goldstein D.S. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004, 25:568-580.
6. Jager P.L., Chirakal R., Marriott C.J., Brouwers A.H., Koopmans K.P., Gulenchyn K.Y. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008, 49:573-586.
7. Fottner C., Helisch A., Anlauf M., Rossmann H., Musholt T.J., Kreft A., et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 2010, 95:2800-2810.
8. Blanchet E.M., Martucci V., Pacak K. Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol 2012, 1:58-66.
9. 68Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol 2012, 22:710-719.